Caliway Biopharmaceuticals Joins Indices, Strengthening Its Position Alongside X.T.L. Biopharmaceuticals Ltd.

Caliway Biopharmaceuticals Strengthens Its Position in the Biotech Landscape

Caliway Biopharmaceuticals Co., Ltd. announces its inclusion in two prestigious indices, the FTSE TWSE Taiwan Mid-Cap 100 Index and the FTSE TWSE Taiwan Eight Industries Index, effective December 23, 2024. This development signals a pivotal moment for the company, highlighting its growing prominence in the biopharmaceutical sector and solidifying its status as a key player within the global biotech landscape. The FTSE TWSE Taiwan Mid-Cap 100 Index is significant as it tracks the top 100 mid-cap firms in Taiwan, excluding the largest 50 companies, thereby shining a spotlight on growth-oriented enterprises like Caliway. Simultaneously, the FTSE TWSE Taiwan Eight Industries Index underscores Caliway's strong foothold across vital sectors, reflecting its commitment to innovation and market leadership.

Caliway’s recognition in these indices not only enhances its visibility among investors but also reinforces its reputation for robust market performance and promising growth prospects. The inclusion serves as a testament to the company's effective strategies in addressing the evolving needs of the healthcare sector. By focusing on developing groundbreaking therapeutic solutions, Caliway aims to improve patient outcomes and deliver value to its stakeholders. This strategic direction positions the company well within Taiwan's dynamic biopharmaceutical industry, as it seeks to capitalize on its innovative pipeline and market leverage.

The FTSE TWSE Taiwan Index Series, a collaboration between the Taiwan Stock Exchange Corporation and FTSE Russell, functions as a critical tool for market participants. It provides real-time indices for trading derivatives, index-tracking funds, and exchange-traded funds, thus facilitating increased engagement in Taiwan's financial markets. Caliway’s inclusion in these indices not only marks a significant milestone in its journey but also reflects its commitment to redefining healthcare through innovative solutions. The company’s growth trajectory is likely to inspire confidence among investors and industry stakeholders alike, fostering a collaborative environment for future advancements in biopharmaceuticals.

In addition to its index recognition, Caliway remains steadfast in its mission to lead the way in therapeutic innovation. The company's focus on research and development underscores its long-term vision of creating impactful healthcare solutions. As it navigates the competitive landscape, Caliway is poised to leverage its enhanced visibility to attract further investment and strategic partnerships.

Overall, Caliway Biopharmaceuticals' recent achievements resonate strongly within the biopharmaceutical community, marking a significant step forward in its quest to contribute meaningfully to global healthcare advancements.